QUALIDADE DE VIDA, ANSIEDADE E DEPRESSÃO EM PACIENTES COM CÂNCER DE COLO DO ÚTERO AVANÇADO
-
Published:2023-06-14
Issue:1
Volume:9
Page:397-411
-
ISSN:2446-922X
-
Container-title:Psicologia e Saúde em Debate
-
language:pt
-
Short-container-title:Psicodebate
Author:
Oliveira Luana Maria da Silva,Barbosa Leopoldo Nelson Fernandes,Filho Breno Augusto Bormann de Souza,Figueiroa José Natal,Mello Maria Júlia Gonçalves de,Azevedo Carla Rameri Alexandre Silva de
Abstract
Objective: evaluate the quality of life (QOL), anxiety and depression scores of patients with cervical cancer treated with neoadjuvant chemotherapy followed by chemoradiotherapy. Methods: prospective cohort study of patients with advanced uterine cervix cancer treated with neoadjuvant chemotherapy followed by radiochemotherapy at a teaching hospital in northeastern Brazil between November 2013 and January 2017. Quality of life was evaluated at four time-points: pre-treatment, after neoadjuvant chemotherapy, after radiotherapy and three months after the end of treatment using Functional Assessment of Cancer Therapy-Cervix (FACT-Cx). Anxiety and depression, we used the Hospital scale of Anxiety and Depression. Results: We studied 40 women, aged 24 to 67 years with an average age of 48 ±11.4 years who had between zero and nine children (mean =3). Most were single (57.5%), illiterate and with elementary school education (85.0%). At the 1st and 4th evaluation, the mean anxiety scores were 7 ±3.5 and 5.5 ±3.6, respectively, and the mean depression scores were 4.4 ±3.2 and 3.7 ±2.6, respectively, with significant variation between the depression scores. The mean FACT-Cx scores at pretreatment were 112.3 ±17.4. At the last evaluation, the mean was 116.3 ±27.6 with a range from 52 to 155, with no significant difference. Conclusion: QOL scores remained stable throughout the treatment. There was a significant variation between the means and proportions of depression, possibly the result of the psychological support offered, demonstrating the importance of follow-up during oncologic treatment, mitigating the impacts of the disease and its treatment. There was no significant difference in anxiety.
Publisher
Psicologia e Saude em Debate
Reference26 articles.
1. Azevedo, C. R. A. S., Thuler, L. C. S., de Mello, M. J. G., de Oliveira Lima, J. T., da Fonte, A. L. F., Fontão, D. F. S., Carneiro, V. C. G., Chang, T. M. C., & Ferreira, C. G. (2017). Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecologic Oncology, 146(3), 560–565. https://doi.org/10.1016/j.ygyno.2017.07.006 2. Azevedo, C. R. A. S., Thuler, L. C. S., de Mello, M. J. G., & Ferreira, C. G. (2016). Neoadjuvant Chemotherapy Followed by Chemoradiation in Cervical Carcinoma: A Review. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 26(4), 729–736. https://doi.org/10.1097/IGC.0000000000000663 3. Bae, H., & Park, H. (2016). Sexual function, depression, and quality of life in patients with cervical cancer. Supportive Care in Cancer, 24(3), 1277–1283. https://doi.org/10.1007/s00520-015-2918-z 4. Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of the Hospital Anxiety and Depression Scale. An updated literature review. Journal of Psychosomatic Research, 52(2), 69–77. https://doi.org/10.1016/s0022-3999(01)00296-3 5. Chase, D. M., Huang, H. Q., Wenzel, L., Cella, D., McQuellon, R., Long, H. J., Moore, D. H., & Monk, B. J. (2012). Quality of life and survival in advanced cervical cancer: A Gynecologic Oncology Group study. Gynecologic Oncology, 125(2), 315–319. https://doi.org/10.1016/j.ygyno.2012.01.047
|
|